

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : A61F 2/28	A1	(11) International Publication Number: WO 99/51170
		(43) International Publication Date: 14 October 1999 (14.10.99)

(21) International Application Number: PCT/US99/05646

(22) International Filing Date: 15 March 1999 (15.03.99)

(30) Priority Data:  
60/080,491 2 April 1998 (02.04.98) US

(71) Applicants (for all designated States except US): CROSS-CART, INC. [US/US]; 3661 Buchanan Street, San Francisco, CA 94123 (US). MCP HAHNEMANN UNIVERSITY [US/US]; Broad & Vine, Mail Stop 485, Philadelphia, PA 19102-1192 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): STONE, Kevin, R. [US/US]; 1 Throckmorton Lane, Mill Valley, CA 94941 (US). GALILI, Uri [US/US]; 9 Woodstream Drive, Wayne, PA 19087 (US).

(74) Agents: LAPPIN, Mark, G. et al.; Lappin & Kusmer LLP, 200 State Street, Boston, MA 02109 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(54) Title: BONE XENOGRAFTS

(57) Abstract

The invention provides an article of manufacture comprising a substantially non-immunogenic bone xenograft (X) for implantation into a defect (D) located in a bone portion (10) of a human. The invention further provides methods for preparing a bone xenograft (X) by removing at least a portion of bone from a non-human animal to provide a xenograft (X); washing the xenograft (X) in saline and alcohol; and subjecting the xenograft (X) to at least one of the treatments including exposure to ultraviolet radiation, immersion in alcohol, ozonic, and freeze/thaw cycling. In addition to or in lieu of the above treatments, the methods include a cellular disruption treatment, and digestion of the carbohydrate moieties of the xenograft (X) with a glycosidase followed by treatment for sialylation.

